The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Orstavik, Oivind ^a   Manfra, Ornella ^a   Andressen, Kjetil Wessel ^a   Andersen, Geir Oystein ^a,b   Skomedal, Tor ^a   Osnes, Jan Bjørn ^a   Levy, Finn Olav ^a   Krobert, Kurt Allen ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ALPHA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CALCIUM ION; CILOSTAMIDE; CYCLIC AMP; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; PHOSPHODIESTERASE III; ROLIPRAM; ACETAMIDE DERIVATIVE; CALCIUM; CARDIOTONIC AGENT; N-(4-(4-METHYL-6-OXO-1,4,5,6-TETRAHYDROPYRIDAZIN-3-YL)PHENYL)ACETAMIDE; PHOSPHODIESTERASE III INHIBITOR; PYRIDAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR CALCIUM; HEART MUSCLE CELL; HEART VENTRICLE; HEART VENTRICLE CONTRACTILITY; INOTROPISM; MALE; NONHUMAN; RAT; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; HEART CONTRACTION; METABOLISM; PHYSIOLOGY; WISTAR RAT;

RATTUS;

ACETAMIDES; ANIMALS; CALCIUM; CARDIOTONIC AGENTS; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 3 INHIBITORS; PYRIDAZINES; RATS, WISTAR;

EID: 84924326401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115547     Document Type: Article

References (39)

1. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, et al. (1995) Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27: 1859-1866. PMID: 8523447
2. Pollesello P, Ovaska M, Kaivola J, Tilgmann C, Lundstrom K, et al. (1994) Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 269: 28584-28590. PMID: 7961805
3. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, et al. (1997) Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 280: 277-283. PMID: 8996207
4. Brixius K, Reicke S, Schwinger RH (2002) Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 282: H131-H137. PMID: 11748056
5. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, et al. (1995) Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113. PMID: 7788868
6. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB (1995) Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25: 794-801. PMID: 7630157
7. Haikala H, Kaheinen P, Levijoki J, Linden IB (1997) The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 34: 536-546. PMID: 9231037
8. Kaheinen P, Pollesello P, Hertelendi Z, Borbely A, Szilagyi S, et al. (2006) Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Basic Clin Pharmacol Toxicol 98: 74-78. PMID: 16433895
9. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, et al. (2001) Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 276: 9337-9343. PMID: 11113122
10. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, et al. (2004) The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486: 67-74. PMID: 14751410
11. Teerlink JR, Metra M, Zaca V, Sabbah HN, Cotter G, et al. (2009) Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 14: 243-253. doi: 10.1007/s10741-009-9153-y PMID: 19876734
12. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, et al. (1998) Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 98: 2141-2147. PMID: 9815868
13. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, et al. (2007) Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9: 75-82. PMID: 16829185
14. Husebye T, Eritsland J, Muller C, Sandvik L, Arnesen H, et al. (2013) Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 15: 565-572. doi: 10.1093/eurjhf/hfs215 PMID: 23288914
15. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ (2002) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40: 465-471. PMID: 12395979
16. Takahashi R, Talukder MA, Endoh M (2000) Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 36: 118-125. PMID: 10892669
17. Takahashi R, Talukder MA, Endoh M (2000) Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 400: 103-112. PMID: 10913591
18. Takahashi R, Endoh M (2002) Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 366: 440-448. PMID: 12382073
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579. doi: 10.1111/j.1476-5381.2010. 00872.x PMID: 20649561
20. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010) Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576. doi: 10. 1111/j.1476-5381.2010.00873.x PMID: 20649560
21. Skomedal T, Borthne K, Aass H, Geiran O, Osnes JB (1997) Comparison between α-1 adrenoceptormediated and β-adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 280: 721-729. PMID: 9023284
22. Skomedal T, Schiander I, Aass H, Osnes JB (1987) Qualitative characteristics of the mechanical response in rat papillary muscles to increase in extracellular calcium concentration. Acta Physiol Scand 131: 347-353. PMID: 2892344
23. Andersen GO, Skomedal T, Enger M, Fidjeland A, Brattelid T, et al. (2004) Alpha1-AR-mediated activation of NKCC in rat cardiomyocytes involves ERK-dependent phosphorylation of the cotransporter. Am J Physiol Heart Circ Physiol 286: H1354-H1360. PMID: 14630635
24. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, et al. (2011) cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res 108: 929-939. doi: 10.1161/CIRCRESAHA.110.230698 PMID: 21330599
25. Di Benedetto G., Zoccarato A, Lissandron V, Terrin A, Li X, et al. (2008) Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ Res 103: 836-844. doi: 10.1161/ CIRCRESAHA.108.174813 PMID: 18757829
26. Marchmont RJ, Houslay MD (1980) A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J 187: 381-392. PMID: 6249268
27. Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, et al. (2014) PDE3-inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol. doi: 10.1111/bph. 12647 [doi].
28. Levy FO (2013) Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility. Naunyn Schmiedebergs Arch Pharmacol 386: 665-670. doi: 10.1007/s00210-013-0874-z PMID: 23649864
29. Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I, et al. (2005) Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 46: 369-376. PMID: 16116344
30. Takahashi R, Endoh M (2005) Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol 145: 1143-1152. PMID: 15951828
31. Afzal F, Aronsen JM, Moltzau LR, Sjaastad I, Levy FO, et al. (2011) Differential regulation of β2-adreno-ceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle. Br J Pharmacol 162: 54-71. doi: 10.1111/j.1476-5381.2010.00890.x PMID: 21133887
32. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, et al. (1993) Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 73: 981-990. PMID: 8222092
33. Sato S, Talukder MA, Sugawara H, Sawada H, Endoh M (1998) Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30: 1115-1128. PMID: 9689586
34. Qvigstad E, Brattelid T, Sjaastad I, Andressen KW, Krobert KA, et al. (2005) Appearance of a ventricular 5-HT4 receptor-mediated inotropic response to serotonin in heart failure. Cardiovasc Res 65: 869-878. PMID: 15721867
35. Garvey JL, Kranias EG, Solaro RJ (1988) Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem J 249: 709-714. PMID: 2895634
36. England PJ (1976) Studies on the phosphorylation of the inhibitory subunit of troponin during modification of contraction in perfused rat heart. Biochem J 160: 295-304. PMID: 188417
37. Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM (2007) Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res 101: 377-386. PMID: 17615373
38. Segreti JA, Marsh KC, Polakowski JS, Fryer RM (2008) Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl) phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J Pharmacol Exp Ther 325: 331-340. doi: 10.1124/jpet.107.132530 PMID: 18171907
39. Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C (2007) Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther 114: 184-197. PMID: 17363065